Subscribe to our Newsletters !!
How are viruses different from bacteria apex ? O
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
Zydus Cadila has obtained final acceptance by the US Food and Drug Administration (USFDA) to advertise Cisatracurium Besylate Injection USP at the potency of 20 milligrams (base)/10 mL (two mg/mL) multiple-dose vial, Cadila Healthcare stated in a regulatory filing on Wednesday.
The drug will be produced in Liva plant of Cadila Healthcare Ltd..
Zydus Cadila is Part of this Cadila Healthcare group.
The team currently has 297 approvals and has up to now registered over 390 abbreviated new drug applications (ANDAs) because the initiation of the filing procedure from FY 2003-04.
Shares of Cadila Healthcare, the listed entity of this group, were trading at Rs 377.60 apiece on BSE, 0.15 percent lower from their previous closure.
